| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRCLINONC.2010.166 |
| P953 | full work available at URL | http://www.nature.com/articles/nrclinonc.2010.166.pdf |
| http://www.nature.com/articles/nrclinonc.2010.166 | ||
| P698 | PubMed publication ID | 20956982 |
| P50 | author | Steven A. Narod | Q50384888 |
| P2860 | cites work | Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. | Q53265333 |
| Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. | Q53509871 | ||
| The contribution of founder mutations in BRCA1 to breast cancer in Belarus. | Q54426242 | ||
| Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. | Q55042194 | ||
| Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women | Q56900447 | ||
| Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing | Q57266657 | ||
| Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group | Q57266745 | ||
| Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia | Q57579994 | ||
| The contribution of founder mutations to early-onset breast cancer in French-Canadian women | Q59238350 | ||
| Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer | Q59238528 | ||
| Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy inBRCA1/2-Associated Stage I/II Breast Cancer | Q59420908 | ||
| Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations | Q61771736 | ||
| Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition | Q63383833 | ||
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition | Q64388338 | ||
| The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin | Q64388522 | ||
| Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil | Q79298338 | ||
| Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus | Q79652358 | ||
| The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy | Q80025885 | ||
| Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes | Q83890421 | ||
| Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers | Q84786183 | ||
| A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas | Q85025815 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer | Q24540270 | ||
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 | ||
| A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment | Q24803679 | ||
| Fine tuning chemotherapy to match BRCA1 status | Q27694529 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 | Q28115843 | ||
| Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer | Q28372484 | ||
| Identification of the breast cancer susceptibility gene BRCA2 | Q29616290 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer | Q33180784 | ||
| Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk | Q33181647 | ||
| Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families | Q33182519 | ||
| Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition | Q33205307 | ||
| Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic | Q33286372 | ||
| The prevalence of BRCA1 mutations among young women with triple-negative breast cancer | Q33419708 | ||
| Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer | Q34110074 | ||
| International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers | Q34116505 | ||
| BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer | Q34145544 | ||
| A high proportion of founder BRCA1 mutations in Polish breast cancer families | Q34548008 | ||
| Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers | Q34548640 | ||
| Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers | Q34579373 | ||
| Ovarian cancer and hormone replacement therapy in the Million Women Study | Q34629811 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| The effect of a single BRCA2 mutation on cancer in Iceland | Q35440029 | ||
| Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers | Q36916140 | ||
| Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging | Q36920323 | ||
| Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers | Q37090813 | ||
| Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo | Q39866244 | ||
| Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. | Q39971672 | ||
| BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance | Q40287564 | ||
| Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer | Q42450903 | ||
| Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype | Q42481495 | ||
| Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy | Q43222794 | ||
| A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families | Q43513698 | ||
| Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations | Q43520691 | ||
| High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia | Q43522641 | ||
| Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom | Q43613838 | ||
| Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. | Q43800820 | ||
| Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada | Q44116893 | ||
| The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania | Q44326522 | ||
| High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. | Q46002818 | ||
| Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group | Q46808117 | ||
| Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update | Q46838391 | ||
| Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group | Q47189470 | ||
| Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations | Q47770236 | ||
| Risk reducing mastectomy: outcomes in 10 European centres. | Q48833793 | ||
| The development of interval breast malignancies in patients with BRCA mutations. | Q50744015 | ||
| Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. | Q50748795 | ||
| Early detection of breast and ovarian cancer in families with BRCA mutations. | Q50757471 | ||
| Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). | Q50761882 | ||
| Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. | Q52123195 | ||
| A high frequent BRCA1 founder mutation identified in the Greenlandic population. | Q53121377 | ||
| The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. | Q53250018 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| BRCA1 | Q227339 | ||
| BRCA2 | Q17853272 | ||
| P304 | page(s) | 702-707 | |
| P577 | publication date | 2010-10-19 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | BRCA mutations in the management of breast cancer: the state of the art | |
| P478 | volume | 7 |
| Q51788159 | 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24. |
| Q37534958 | A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA. |
| Q36487269 | A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25. |
| Q57108063 | Advances in the use of PARP inhibitor therapy for breast cancer |
| Q90375515 | BRCA testing in unaffected young women in the United States, 2006-2017 |
| Q37052120 | BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. |
| Q34283643 | BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane |
| Q33829394 | BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population |
| Q64104592 | BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells |
| Q57112840 | Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis |
| Q38389226 | Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. |
| Q26766205 | Breast cancer survival among young women: a review of the role of modifiable lifestyle factors |
| Q38991293 | Can we prevent BRCA1-associated breast cancer by RANKL inhibition? |
| Q43989797 | Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer |
| Q36630732 | Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview |
| Q36105474 | Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes |
| Q35713872 | Clinical Significance of Age at the Time of Diagnosis among Young Breast Cancer Patients |
| Q57700816 | Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS |
| Q44323635 | Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer |
| Q91873323 | Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients |
| Q38665032 | Crucial considerations for pipelines to validate circulating biomarkers for breast cancer |
| Q38874006 | Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells |
| Q52682549 | Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada). |
| Q35208929 | Drug therapy for hereditary cancers |
| Q22242858 | Epigenetic changes of DNA repair genes in cancer |
| Q40044373 | Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study. |
| Q34451291 | Evaluating genomic tests from bench to bedside: a practical framework |
| Q35477949 | Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population |
| Q29249088 | Familial risk for lung cancer |
| Q38024316 | Folate and breast cancer: what about high-risk women? |
| Q34530426 | Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review |
| Q33564013 | Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting |
| Q38241489 | Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: surgical options for personalized care |
| Q34354159 | How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diag |
| Q38062611 | IGF-1 and BRCA1 signalling pathways in familial cancer |
| Q33849329 | Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer |
| Q35472154 | Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. |
| Q35550054 | Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. |
| Q35440379 | In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein |
| Q35105959 | In their own words: treating very young BRCA1/2 mutation-positive women with care and caution |
| Q36110001 | Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option |
| Q46104940 | Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests |
| Q44577463 | Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. |
| Q57113809 | Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention - a Narrative Review |
| Q34670535 | Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum |
| Q38216131 | Nucleic acid-based tissue biomarkers of urologic malignancies |
| Q37018223 | Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. |
| Q36693272 | Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment |
| Q37379906 | Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve |
| Q95725188 | Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers |
| Q35130901 | Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study' |
| Q40970978 | Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin |
| Q40287145 | Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? |
| Q90676391 | Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients |
| Q37672307 | Seeking Genomic Knowledge: The Case for Clinical Restraint |
| Q35687208 | Skp2 is a promising therapeutic target in breast cancer |
| Q36755366 | Systemic treatment for hereditary cancers: a 2012 update |
| Q37600675 | Tamoxifen for women at high risk of breast cancer |
| Q36218446 | The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers |
| Q51062456 | The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers. |
| Q30677729 | The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--a population-based data linkage study |
| Q34481713 | The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling |
| Q38314472 | The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers |
| Q44256039 | Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers |
| Q21296683 | Tumor angiogenesis: pericytes and maturation are not to be ignored |
| Q37941372 | Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer |
| Q38371909 | Use of BRCA Mutation Test in the U.S., 2004-2014. |
| Q88219476 | Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study |
| Q36544789 | miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers |
| Q89842473 | miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil |
| Q36638226 | p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes |
Search more.